

ECHA DECLARATION OF INTEREST

There is a conflict of interest where the impartiality and objectivity of a decision, opinion or recommendation of the Agency and/or its bodies, is or might in the public perception be compromised by an interest held by, or entrusted to, an individual working for the Agency.

Please note that having an interest does not necessarily mean having a conflict of interest. In particular, high quality of (scientific) expertise is by nature based on prior experience. Declaring an interest does therefore not automatically disqualify you or limit your participation in the activities of the European Chemicals Agency.

On the other hand it should be emphasised that this declaration of interest form does not contain an exhaustive list of potential interests and that all other elements that might jeopardise your independence when working with the Agency should thus also be indicated. Your answers will then be reviewed and dealt with in accordance with the ECHA Procedure for Prevention and Management of potential Conflicts of Interest.

Declaration of Commitment

I hereby declare that I shall make all reasonable efforts to fulfil my duties related to the work of the European Chemicals Agency.

Declaration of Interests

First Name: Jānis

Last name: Ločs

Position in ECHA: SEAC member

hereby declares to have the following interests:

I. Employment, consultancy, legal representation or advice

Within the past 5 years, were you employed or have you had any other professional relationship with a commercial entity¹ or other organisation² with an interest in the regulatory field of activity of ECHA?

- No
 Yes, and more in particular:

Function/Activity	Time period (from...until month/year)	Name of organisation or commercial entity	Description
Research and development in the field of materials science and chemical engineering	From 07/2007 until now.	Riga Technical University, Latvia	Research and development in the field of implant materials - medical devices.

II. Membership of Governing Body, Scientific Advisory Body or equivalent structure

Within the past 5 years, have you participated in the internal decision-making of a commercial entity or other organisation with an interest in the regulatory field of activity of ECHA (e.g. board membership, directorship) or have you participated in the works of a Scientific Advisory Body with voting rights on the outputs of that entity?

- No
 Yes, and more in particular:

Function/Activity	Time period (from...until month/year)	Name of organisation or commercial entity	Description

¹ This includes any commercial business, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

² An 'organisation' includes governmental, international or non-profit organisations, as well as interest groups.

III. Other membership or affiliation

Within the past 5 years, have you had any membership or affiliation other than the above that can be perceived as creating a potential conflict of interest?

No

Yes, and more in particular:

Function/Activity	Time period (from...until month/year)	Name of organisation or commercial entity	Description

IV. Research funding

Within the past 5 years, have you or the research entity to which you belong received any support from a commercial entity or other organisation with an interest in the regulatory field of activity of ECHA, including grants, rents, sponsorships, fellowships, non-monetary support?

No

Yes, and more in particular:

Function/Activity	Time period (from...until month/year)	Name of organisation or commercial entity	Description

V. Investments

Do you have current investments in a commercial entity with an interest in the regulatory field of activity of ECHA, including holding of stocks and shares, stock options, equity, bonds, partnership interest in the capital of such undertaking, one of its subsidiaries or a company in the capital of which it has a holding and which amounts to more than 10,000 EUR per commercial entity or entitling you to a voting right of 5% or more in such commercial entity?³

- No
 Yes, and more in particular:

Investment	Name of organisation or commercial entity

VI. Intellectual Property

Do you have any intellectual property rights (e.g. patent, trademark, copyright or proprietary know-how) in the regulatory field of activity of ECHA that might create a potential conflict of interest?

- No
 Yes, and more in particular:

Intellectual Property	Name of organisation or commercial entity	Description
J.Ločs, L.Berziņa-Cimdīņa, A.Škaģers, D.Loča, I.Šalma, Ģ.Šalms. Device and method for impregnation and/or coating of porous implant materials with substances. Pat., No. LV 14256 (20.04.2011)	Riga Technical University	Offered a new implant impregnation and / or coating device and method referable to the medical field, mainly in orthopedics, traumatology, dentistry, face, jaw and other hard porous bone tissue surgery. It is multifunctional and is based on controlled impregnation of the implant open pores and / or implant coating with one or more of the necessary substances (pharmaceuticals, polymers, suspensions, etc. applicable to agents) under depression conditions. Impregnation parameters are set according to the choice of implant and

³ You may exclude financial interests held through an investment fund, pension fund and/or interests in non-nominal unit trusts or similar arrangements, provided that these investments are broadly diversified and you have no influence on their financial management.

		substance (impregnation and / or coating substances), physical-chemical properties (porosity, capillary forces, viscosity, etc.). The device is characterized by the fact that it is compact, simple and economical in operation, equipped with a graduated dropping funnel and vacuum pump, includes interrelated functional parts what form hermetically sealed system, which allows to maintain sterility throughout whole process.
Z.Irbe, L.Berziņa-Cimdina, J.Ločs, D.Loča. Method for the preparation of calcium phosphate bone cements. <i>Pat.</i> , No. LV 14592 (18.05.2012)	Riga Technical University	Proposed calcium phosphate bone cement and method for its preparation contributes to the field of medicine and can be used for surgical reconstruction of trabecular bone defects in non-load bearing sites, also as scaffolds for bone tissue engineering and as material for drug delivery system preparation. For preparation of calcium phosphate cement plastic mass, the solid phase is synthesized α -tricalcium phosphate (α -TCP), mass content 90 – 99% with β -TCP $\leq 10\%$ admixture. The liquid phase is sodium or potassium hydrogen phosphate and dihydrogen phosphate (or corresponding hydrates) water solutions.
A. Pūra, L.Bērziņa-Cimdiņa, J.Ločs, I.Freimanis. Ceramic paste of titanium dioxide. <i>Pat.</i> , No. 14365 (11.04.2011)	Riga Technical University	Proposed TiO ₂ ceramic mass composition refers to the technical ceramics industry and manufacturing of design elements for producing of electro-radiotechnical and chemical industries in various forms and structures for construction elements via extrusion technology. Ceramic composition is characterized by the fact that for the preparation of the ceramic mass, natural material anatase and shredded low quality products after firing (rutile crystal modification) as (%) anatase: rutile 80-90:20-10 is used.

<p>J.Ločs, V.Zālīte, I.Freimanis, L.Bērziņa-Cimdiņa, A.Skaģers. Porous hydroxyapatite ceramics with a bimodal pore distribution and fabrication of the same. <i>Pat.</i>, No. LV14492 (20.07.2012)</p>	<p>Riga Technical University</p>	<p>The proposed preparation method of porous HAp ceramics with a bimodal pore distribution is attributed to the medical industry, traumatology and orthopedics, maxillofacial surgery, as a scaffolds for tissue engineering or drug delivery systems, as well as a filler in bone (spongy parts) defects. HAp powder is used as basic material, glycerol as plasticizer, deionized water as moisturizing agent, and ammonium bicarbonate as a pore-former substance. Ceramic manufacturing technology is based on the foaming process <i>in situ</i>.</p>
<p>EP13179914.0. Invention "Method for producing monolithic titanium suboxide TiO_x ceramic electrode for water electrochemical treatment and electrode produced", Nr.: LAP 1354. Inventors: Ozolins J., Locs J., Reimanis M., Juhna T., Mezule L., Sadretdinovs R., Berzina-Cimdina L.</p>	<p>Riga Technical University</p>	<p>The invention relates to a method for producing monolithic titanium suboxide TiO_x ceramic electrode for water electrochemical treatment and to an electrode produced using this method.</p>
<p>CA2985182 (A1) – 2016-11-10, Invention. "Method for manufacturing bone implant and bone implant". SWIESZKOWSKI WOJCIECH [PL]; CHUDOBA TADEUSZ [PL]; KUSNIERUK SYLWIA [PL]; KEDZIERSKA ALEKSANDRA [PL]; WOZNIAK BARTOSZ [PL]; ROGOWSKA-TYLMAN JULIA [PL]; SMOLEN DARIUSZ [PL]; PIETRZYKOWSKA ELZBIETA [PL]; LOJKOWSKI WITOLD [PL]; WOJNAROWICZ JACEK [PL]; GEDANKEN AHARON [IL]; LOCS JANIS [LV]; ZALITE VITA [LV]; PILMANE MARA [PL]; SALMA ILZE [LV]</p>	<p>INST WYSOKICH CISNIEN POLSKIEJ AKADEMII NAUK [PL]</p>	<p>The method of making an implant consists on coating of a supporting structure with synthetic hydroxyapatite by immersing the supporting structure in a suspension and triggering of a cavitation in a portion of the suspension being in contact with the supporting structure. The suspension is formed by a liquid external phase, advantageously water, and internal phase, i.e. particles of synthetic hydroxyapatite having an average particle size not exceeding 100 nm and containing structural water in an amount from 2 to 6% by weight. The implant is coated with the above described hydroxyapatite subjected to cavitation and a thickness of 50 nm to 1000 nm, advantageously 50 nm to 300 nm.</p>
<p>LV15060 (A) – 2015-10-20. Invention. "Remedy for</p>	<p>RĪGAS STRADIŅA UNIVERSITĀTE [LV];</p>	<p>The invention refers to medicine, specific to orthopedic surgery.</p>

<p>reinforcement of bone defects in osteoporosis"</p>	<p>RĪGAS TEHNISKĀ UNIVERSITĀTE [LV]</p>	<p>The composition of biphasic calcium phosphate bioceramic material out of synthetic hydroxyapatite and tricalcium phosphate Hap/TCP? 90/10 granules is invented and can be used as a local reinforcement of osteoporotic bone in cases of fractures.</p>
---	---	--

VII. Public statements and positions

Within the past 5 years, have you provided any expert opinion or testimony in the regulatory field of activity of ECHA for a commercial entity or other organisation as part of a regulatory, legislative or judicial process? Have you held an office or other position, paid or unpaid, where you represented interests or defended an opinion in the regulatory field of activity of ECHA?

- No
 Yes, and more in particular:

Function/Activity	Time period (from...until month/year)	Name of organisation or commercial entity	Description

VIII. Other relevant information

Are there any other elements that could be seen as jeopardising your independence when working for the Agency?

- No
 Yes, and more in particular:

IX. Interests held by close family members⁴

Do any of your close family members hold any current interests in the regulatory field of activity of the Agency (as specified above in the sections I.-VIII.)?

No

Yes, and more in particular:

Function/Activity	Name of organisation or commercial entity	Description

I wish to have any reference to interests held by close family members removed if this declaration is to be made public on the ECHA website.⁵

I hereby declare that I have read both the ECHA Procedure on Prevention and Management of potential Conflicts of Interest and the related ECHA Guidance document and that the above Declaration of Interest is at my best knowledge complete. I understand that for all members of the ECHA bodies, the Executive Director and the other ECHA management staff (Directors and Heads of Unit), as well as for the chairpersons of the ECHA Committees this declaration will be published on the ECHA website.

Please note that the European Chemicals Agency will ensure on its part that your personal data hereby submitted is processed as required by [Regulation \(EC\) No 45/2001 on the protection of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free movement of such data](#). The data is necessary for the purpose of implementing the Agency's Procedure for Prevention and Management of potential Conflicts of Interest and will be retained for a time period of 7 years. You have the right to access and rectify that data. Under certain conditions, a right to erasure, restriction, objection and/or data portability also applies. To exercise these rights, please contact the relevant secretariat. You can contact the Agency's [Data Protection Officer](#) for any questions or complaints with regard to the processing of your personal data. In case you do not receive a satisfactory outcome, you can have recourse to the [European Data Protection Supervisor](#).

Date:21.03.2018

⁴ For this purpose, 'close family members' are considered to be the persons forming a household with the person making this declaration (spouse, partner, and/or dependent children). For privacy reasons neither the relationship nor the name is to be included. Only current interests held by close family members are of relevance and not past interests.

⁵ As full transparency is one of the general principles of this Procedure, this option should only be used in case the consent of the individual concerned has not been obtained, when he/she has objected to the disclosure on compelling legitimate grounds or if there is reason to believe that the legitimate interests of the individual involved might be prejudiced by the disclosure (see also Regulation (EC) No 45/2001 on the protection of personal data).